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Objective: The Coronavirus Disease (COVID-19) pandemic and related lockdown measures 
have raised important questions about the impact on mental health. This study evaluated several 
mental health and well-being indicators in a large sample from the United Kingdom (UK) during 
the COVID-19 lockdown where the death rate is currently the highest in Europe. 
 
Methods: A cross-sectional online survey with a study sample that mirrors general population 
norms according to sex, age, education, and region was launched four weeks after lockdown 
measures were implemented in the UK. Measures included mental health-related quality of life 
(WHO-QOL BREF psychological domain), well-being (WHO-5), depression (PHQ-9), anxiety 
(GAD-7), perceived stress (PSS-10), and insomnia (ISI). ANOVAs, Bonferroni-corrected post-
hoc tests, and t-tests were applied to examine mental health indicators across different 
sociodemographic groups (age, sex, employment, income, physical activity, relationship status). 
 
Results: The sample comprised N=1,006 respondents (54% women) from all regions of the UK. 
Approximately 52% of respondents screened positive for a common mental disorder, and 28% 
screened positive for clinical insomnia. Mean scores and standard deviations were as follows: 
PHQ-9: M=9.0±7.7; GAD-7: M=8.0±6.5; ISI: M=10.4±7.0; PSS-10: M=17.7±7.9; WHO-QOL 
BREF: M=58.6±21.4; WHO-5 score M=13.0±6.0. Statistical analyses consistently indicated 
more severe mental health problems in adults under 35 years, women, people with no work, and 
low income (all p-values <.05). Mental health indices also varied across UK regions. 
 










Conclusions: The prevalence of depressive-, anxiety-, and insomnia symptoms is significantly 
higher in the UK, relative to pre-pandemic epidemiological data. Further studies are needed to 
clarify the causes for these high rates of mental health symptoms.    
 
Keywords: Mental health, depression, anxiety, insomnia, UK, COVID-19 
 
Abbreviations: PHQ-9: Patient Health Questionnaire; GAD-7: Generalized Anxiety Disorder 7 
scale; ISI: Insomnia Severity Index; WHO-QOL BREF: World Health Organization Quality-of-
life (psychological domain) brief version; WHO-5: World Health Organization Well-Being Index  











The Coronavirus disease 2019 (COVID-19) has spread quickly throughout the world. (1) In 
Europe alone, there are currently (3th of May 2020 at 10:00 CET) around 1.5 million confirmed 
COVID-19 cases and around 140,000 confirmed deaths. (2) In the UK, data released by the 
Office for National Statistics showed that 29,648 deaths registered in England and Wales with 
COVID-19 mentioned on the death certificate by 2nd of May. With the addition of the official 
death figures for Scotland and Northern Ireland, this was calculated to take the UK’s toll to 
32,313 (3), a figure viewed as the highest in Europe. The true figure is likely to be significantly 
higher due to missed cases and a lag in reporting.  
 
As COVID-19 spreads easily between people who are in close contact (1), most 
governments have implemented restrictions to prevent the uncontrolled spread of the virus. 
Although social distancing and other measures such as the use of personal protective equipment 
could help to contain the uncontrolled spreading of COVID-19 (1), they might negatively affect 
mental health. (4)  
 
There is a rapidly increasing number of publications on mental health during the COVID-
19 pandemic. Many of them are commentaries about poor mental health due to COVID-19. (5) It 
is highly likely that many individuals feel stressed and worried in times of pandemics, with fears 
of falling ill or dying, being socially excluded in quarantine, or losing their income. Although 
such reactions may not necessarily impair functioning or general well-being, it is not clear to 
what extent such circumstances precipitate severe symptoms of mental disorders that warrant 
clinical care. 











There is an increasing number of studies examining the effect of the COVID-19 
pandemic on mental health, initially from Asian and European countries, and now also from 
other regions worldwide. Some of these have been published in scientific journals, and some 
have not been peer reviewed. Four observational studies on mental health in China have been 
reviewed recently and results showed anxiety and depression symptoms (16–28%) as well as 
stress-levels (8%) being common mental health problems during COVID-19. (6) In Japan, a 
representative population survey reported poorer mental health indicators in young and middle-
aged individuals (relative to older people), as well as in unemployed individuals. (7) In India, 
high scores for depression, anxiety, and stress were also found, especially in younger adults. (8)  
 
Findings from European countries appear to be generally consistent in identifying 
sociodemographic and lifestyle-related risk factors. An Italian survey found that poor mental 
health indicators were particularly acute in women and younger people. (9) A Portuguese study 
examining protective lifestyle factors indicated that people who were able to work, those who 
exercised frequently, and those without previous psychological or physical health problems had 
relatively better well-being indicators. (10) Cross-sectional surveys conducted in the UK in the 
early phase of the lockdown indicate that quarantine measures were associated with poor mental 
health, well-being and quality of life, especially in younger people, those with children at home, 
and those with pre-existing health problems. (11,12)  
 
According to the World Health Organization (WHO) COVID-19 official information, the 
United Kingdom (UK) is among the most affected countries in Europe. (2) The aim of the 










current study was to evaluate a broad set of mental health and well-being indicators in a 
representative UK adult sample, measured during the acute phase of the pandemic and four-
weeks after the imposition of lockdown (quarantine) measures. Relevant sociodemographic 





A cross-sectional online survey was designed to recruit a UK study sample that mirrored general 
population norms according to sex, age, education, and region. The survey was launched using 
the Qualtrics® population survey platform, measuring several mental health and well-being 
indicators during the COVID-19 lockdown. Data collection started four-weeks after quarantine 
measures were implemented in the UK, and data were collected until the point where a sample 
was obtained with a minimum sample size of N=1,000, which was specified a priori. 
Participants were contacted by the project team who organized and coordinated data collection. 
As part of the scoping process, Qualtrics implemented age, sex, educational, and regional quotas 
based on UK population census data. Overall, the target sample was attained within ten days, 
after which the survey closed. COVID-19 lockdown was officially implemented in the UK on 
24th of March 2020, and the survey started on 21st of April 2020.  
 
Ethical considerations 
This study was conducted in accordance with the Declaration of Helsinki and approved by to the 
Ethics Committee of the Danube University Krems (approval code: EK GZ 26/2018-2021). All 










participants gave electronic informed consent for participation and before completing the 
questionnaires. Data were collected anonymously without IP addresses or GPS tracking, and this 
procedure was approved by the data protection officer of the Danube-University Krems, Austria.  
 
Governmental restrictions during the survey 
In the UK, COVID-19 social distancing measures became obligatory on 24th of March 2020. The 
UK population was required to adhere to quarantine with only the following exceptions 
justifying leaving the house: shopping for food and other necessities; exercising alone or with 
someone from the same household; for medical reasons including providing care to others; and 
traveling to and from work.  
 
Study sample 
In total, we collected data for N=1,006 participants across all regions of the UK, yielding a study 
sample that reflected general population norms according to sex, age, education, and region, as 
described above. Demographic characteristics of the study sample are presented in Table 1. 
 
Measures 
Quality of Life 
The WHOQOL-BREF provides a reliable, valid, and brief assessment of quality-of-life. (13) The 
26 items self-rating questionnaire measures physical health, psychological health, social 
relationships, and environment during the past two weeks. Only the psychological domain (6 
items) was used in the present study as an indicator of mental quality of life. The general 










population norm for the WHOQOL-BREF psychological domain has been reported to be 70.6 
(14.0). (14) Cronbach’s alpha for the psychological domain was α = .88 in the current sample. 
 
Well-being 
Well-being was measured with the WHO-5 Well-Being Index, which measures subjective 
psychological well-being within the last two weeks, using five self-rating items on six-point 
Likert scales; a higher score indicates better well-being (Example item: “I have felt active and 
vigorous”). The WHO-5 has well-established reliability and validity. (15) The raw score can 
range from 0 (absence of well-being) to 25 (maximal well-being). Cronbach’s alpha was α = .91 
in the current sample. 
 
Perceived stress 
Perceived stress (i.e., the subjective perception of the stress-level) was measured with the PSS-
10, which includes 10 items on a five-point scale ranging from 0-4. (16) Participants are asked to 
rate their stress-level over the last month (Example item: “In the last month, how often have you 
felt nervous and ‘stressed’”?). The PSS-10 is a reliable and valid tool measure stress-level. 
Cronbach’s alpha was .88 in the current sample. 
 
Depressive symptoms 
Depressive symptoms were measured with the depression module of the Patient Health 
Questionnaire, the PHQ-9. (17) This validated screening tool for depression has 9 self-rating 
items on a four-point scale, scored from 0 to 3, which yields a total severity score between 0 and 
27. Clinical cut-off points are 5 for mild depression, 10 for moderate depression and at least 15 









for moderate to severe depression. The 10-point cut-off score was used in the present study to 




Anxiety symptoms were measured with the Generalized Anxiety Disorder 7 scale (GAD-7). (18) 
This validated screening tool for anxiety has 7 self-rating items on a four-point scale, from 0 to 
3, yielding a total anxiety severity score between 0 and 21. Clinical cut-off points are 5 for mild, 
10 for moderate and 15 for severe anxiety symptom levels. The 10-point cut-off score was used 




The Insomnia Severity Index (ISI) is a validated 7-item self-report scale with a five-point scale 
(from 0 to 4) measuring sleep quality and insomnia. (19) Symptom severity categories are: no 
clinically significant insomnia (0 – 7 points), subthreshold insomnia (8 – 14 points), clinical 
insomnia (moderate severity) (15 – 21 points), and clinical insomnia (severe) (22 – 28 points). 
The cut-off score of ≥ 15 was used to define moderate (i. e., clinically relevant) insomnia in this 
study. Cronbach’s alpha was α = .91 in the current sample. 
 
Sex, age group, employment, income, relationship status and region 
Participants had to self-report their sex, age group (18-24; 25-34; 35-44; 45-54; 55-64; 65+ 
years), if they were in paid employment during the lockdown restrictions (No, and did not before 










the lockdown either; No, but before the lockdown I did; Yes, in Home-Office; Yes, as before at 
my workplace (not in my Home Office); Yes, but I've been put on reduced hours; I am retired), 
the net monthly income in their household (< GBP 900,-; GBP 900,- to GBP 1,800,-; GBP 
1,800,- to GBP 2,700,-; GBP 2,700,- to GBP 3,600,-; > GBP 3,600,-), physical activity in the last 
7 days (0; 1; 2; 3; 4 or more days), relationship status (category 1 including being single, 
separated, divorced and widowed; category 2 including married and living as married), and 
region (North East; North West; Yorkshire & Humber; East Midlands; West Midlands; East of 
England; London; South East; South West; Wales, Scotland; Northern Ireland). 
 
Statistical analysis  
Descriptive statistics were computed for the demographic characteristics and mental health 
scales. Based on the literature, we applied the cut-off ≥ 10 to examine the proportion of cases 
with clinically relevant depression (PHQ-9) and anxiety (GAD-7) symptoms. In addition, to aid 
comparability with epidemiological data, the recommended case-finding cut-off scores of PHQ-9 
≥ 10 (17) or/and GAD-7 ≥ 8 (18) were applied to identify the proportion of cases likely to meet 
diagnostic criteria for any common mental disorder (CMD). The 8-point cut-off (and not the 10-
point cut-off) was selected for the GAD-7 to identify likely CMD cases, since it has adequate 
sensitivity (77%) and specificity (82%). (18) For the PHQ-9, the 10-point cut-off shows adequate 
sensitivity (88%) and specificity (88%). (17) This approach classified likely CMD cases if they 
scored above the case-finding threshold in one or both of these measures. 
 
ANOVAs, Bonferroni-corrected post-hoc tests, and t-tests for independent samples were 
calculated to evaluate differences in mental health indicators, comparing different groups 










according to sociodemographic and lifestyle variables (sex, age, work situation, income, physical 
activity, relationship status). For t-tests, between-group effect sizes were calculated with a 
correction for imbalanced samples (Hedge´s g), which can be interpreted as follows: small effect 
(g = .2 to .5), medium effect (g ≥ .5 to .8), and large effect (g ≥ .8). For ANOVAs, η2 was used 
for between-group effect sizes, which can be interpreted as follows: small (η2 = .01 to .06), 
medium (η2 ≥ .06 to .14), and large (η2 ≥.14). Chi-squared tests were performed to evaluate 
differences in the distribution of cases across mental health severity categories between different 
sociodemographic groups. P-values <0.05 were considered statistically significant (2-sided tests). 
Given the relatively low sample sizes for less densely populated regions of the UK, regional 
differences were not statistically tested, but the variability in indices of mental health across 
regions was summarized and examined visually using heat maps. 
 
All data were analyzed using SPSS version 24. 
 
Results  
Sample characteristics are presented in Table 1.  
 
- Table 1- 
 
The statistical distributions of mental health and well-being indices in the study sample are 
presented in Tables 2–7. These Tables also report statistical comparisons in mental health indices 
according to sex (Table 2), age (Table 3), work situation (Table 4), income (Table 5), physical 










activity (Table 6), and relationship status (Table 7). The results of between-group comparisons 
are summarized below. 
 
Demographics 
The effect of sex was significant for all indicators of mental health, indicating that women were 
more burdened than men (p<.05).  
 
- Table 2- 
 
In addition, the effect of age was significant for all indicators (p<.001), as shown in Table 3. 
Bonferroni-corrected post-hoc tests (Table S1, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A689) showed that younger individuals were most burdened and 
those aged 65+ years were least burdened (p<.05).  
 
- Table 3- 
 
Work and income 
As is shown in Table 4, the associations with work were significant for all indicators of mental 
health (p<.001). According to Bonferroni-corrected post-hoc tests (Table S2, Supplemental 
Digital Content, http://links.lww.com/PSYMED/A689), retired individuals were least burdened 
(p<.05).  
 
- Table 4- 











Table 5 shows that the associations of income with depression and anxiety symptom severity 
categories were not significant (p>.05), but significant associations were found between income 
with insomnia severity categories and all continuous scales used to measure mental health 
(p<.05). According to Bonferroni-corrected post-hoc tests (Table S3, Supplemental Digital 
Content, http://links.lww.com/PSYMED/A689), less income was related to worse overall mental 
health (p<.05). 
 
- Table 5 - 
 
Social and lifestyle factors 
Physical activity was significantly associated with all symptom severity categories (all p values 
<.05) (Table 6). Physical activity was also significantly related to all continuous scales used to 
measure mental health (p≤.001), except for anxiety and stress (p>.05). According to Bonferroni-
corrected post-hoc tests (Table S4, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A689), more physical activity was related to better mental health 
(p<.05). 
 
- Table 6 - 
 
Table 7 shows that relationship status was significantly associated with depression and anxiety 
symptom severity categories (p<.01), but not with insomnia symptom severity categories 
(p>.05). Relationship status was also significantly associated with all mental health scale scores 










(p<.01) except for insomnia (p>.05). Those married or living as married had better mental health 
than those who were not married or not living as married (including single, separated, divorced 
and widowed respondents). 
 
- Table 7- 
 
Regional variations 
A heat map showing mean depression symptom scores (and standard deviations) for each UK 
region is presented in Figure 1. The severity of depression varied across regions, with the lowest 
indices in the south west, and the highest indices in the south east, north east and Wales. Visual 
inspections for other indices of mental health were largely consistent with the findings observed 
for depression. 
 
- Figure 1 - 
 
Discussion 
The prevalence of depression, anxiety, and insomnia symptoms is significantly higher in the UK, 
relative to pre-pandemic epidemiological data. The present study indicates that the point-
prevalence of respondents meeting threshold for any common mental disorder (PHQ-9 ≥ 10 
and/or GAD-7 ≥ 8) in the acute phase of COVID-19 is 52%, albeit using self-rated 
questionnaires rather than diagnostic interviews. In contrast, the prevalence of UK adults 
meeting diagnostic threshold for any common mental disorder before COVID-19 was ~17%, and 
this is a stable estimate relative to earlier epidemiological surveys that used structured diagnostic 









interviews. (20). If we compare our results to other UK studies that used self-rated screening 
tools, earlier pre-pandemic samples report a point-prevalence of anxiety or depression symptoms 
of around 20% for respondents aged 16 or older. (21).  
 
Regarding depression specifically, a previous study on individuals aged 15 or older using 
a self-rated screening tool reported a depression prevalence rate of 7% in the UK. (22) In 
contrast, 41% of the present study sample showed clinically relevant depressive symptoms 
(PHQ-9 ≥ 10) and 39% showed clinically relevant anxiety symptoms (GAD-7 ≥ 10). This is 
much higher than available pre-pandemic general population data in Europe (anxiety disorders: 
14%; major depression: 6.9%). (23) Furthermore, 28% of the sample scored above the cut-off for 
clinical insomnia (moderate severity) on the ISI. According to a meta-analysis, the pre-pandemic 
prevalence of insomnia in Europe was around 7%. (23) For the sample as a whole, the average 
PHQ-9 and GAD-7 scores of 9.0 and 8.0 respectively approximate the cut-offs for clinically 
relevant depression and anxiety symptoms respectively, and average insomnia symptoms are 
already above the cut-off for sub-threshold insomnia. 
 
The psychological health score (58.6) on the WHO-QOL BREF questionnaire was below 
the norm value of 70.6 reported by Hawthorne and colleagues. (14) Similarly, with a score of 13, 
well-being (WHO-5) was lower compared to a previous study from Denmark showing converted 
scores of 17. (24) The stress-level (18) was higher compared to a previous study reported scores 
of 13 for a representative sample (not UK but Germany) by Klein and colleagues. (25) 
 










To our knowledge, two previous UK surveys have been published as pre-print reports. 
The study by Shevlin et al. surveyed a general population sample using the same mental health 
measures (PHQ-9, GAD-7) during the earliest phase of the pandemic, reporting a point-
prevalence of 22.1% clinically relevant depression and 21.6% anxiety cases respectively. (11) 
Relative to these figures, the present study indicates that mental health indicators worsened over 
time, as the pandemic progressed into the acute phase four-weeks after lockdown. This 
corresponds to findings of a review that mental health is affected more when restrictions last 
longer. (4) The study by White and Van der Boor used a different measure (Hospital Anxiety and 
Depression Scale), so direct comparison is not possible, but their results also indicated that mean 
levels of depression and anxiety symptoms during the COVID-19 pandemic were elevated 
relative to available pre-pandemic normative data. (12) Overall, data emerging from the UK 
consistently indicate that the mental health of the general population during the COVID-19 
pandemic was considerably poorer relative to available pre-pandemic indicators, and it appears 
that it has gradually deteriorated over the first four weeks since the implementation of lockdown 
measures. 
 
There was a clear age-related effect in all tested mental health scales. These results are 
noteworthy and warrant more detailed consideration. For each aspect of mental health, the 
younger adult groups showed the worst scores and the older people the best. This is, perhaps, 
surprising in the context of COVID-19, since older people are more seriously physically 
threatened by COVID-19. Although the PHQ-9 is generally stable throughout all periods of 
adulthood, (26) two-thirds (63%) of people aged between 18 and 24 years showed depressive 
symptoms, compared to 11.5% in the age group 65+. Similarly, rates of anxiety symptoms are 










59% in the age group from 18 to 24 vs. 12% in the group 65+. For insomnia symptoms there is 
also a decrease in the course of life, from 35% (age 18-24) to 13% (age 65+). Accordingly, the 
youngest age group (18 - 24) showed the lowest scores in psychological well-being. The 
differences are very marked; 47 vs. 71 (in the 65+ group). The same was observed with the 
WHO-5 questionnaire (11 vs. 15). In essence, older adults seem to be handling this exceptional 
situation better than younger ones. Possible explanations for these findings include more 
uncertain working conditions and therefore more serious financial problems for younger people, 
but also the impact of the lockdown on freedom of movement is likely to have a greater 
immediate impact for the lifestyle of younger people. In addition, older people may have a 
context of growing up in post-war years that made the current situation more familiar. But 
whatever the reasons, these results seem robust and are in line with several studies in other 
countries such as China, Japan, Italy, and Portugal. For the UK, this age effect has also been 
reported in the survey by Shevlin et al. during the earliest phase of the COVID-19 pandemic. 
(11) 
 
Besides age, sex also shows an impact on mental health. Women scored worse in every 
tested scale compared to men. For example, 46.7% of women scored above the PHQ-9 cut-off 
greater-equal 10 points for depressive symptoms and 34.6% of men (35% more burden in 
women). Pre-pandemic values for the UK were 8.6% for women and 6.1% for men (41% more 
burden in women). (22) These results are in line with previous studies; sex differences in mental 
health are among the most intriguing and stable findings in psychiatry. (27) 
 










Our results indicate that unemployed and low-income respondents had poorer mental 
health, and regional variations in the severity of depression were consistent with known regional 
variations in socioeconomic deprivation. These results are in line with previous findings on 
socioeconomic deprivation and mental health. People with mild to moderate mental illness, such 
as anxiety or depression, are twice as likely to be unemployed. (28) Unemployment rates for 
people with a severe mental disorder are five times as high as for people without a mental 
disorder. (28) In addition, the relationship status showed an expected effect due to social 
isolation. A recent review showed that relationship or marriage improves mental health. (29) 
Associations between physical activity and mental health have often been reported. (30) 
 
The present results should be interpreted in the context of some limitations. First, the 
cross-sectional design allows no causal conclusions. A baseline stage immediately before the 
implementation of lockdown measures would have been a better control to study changes in 
mental health, but of course the spread of the pandemic was unforeseen – a ‘black swan’ event – 
so the circumstances require us to learn from limited available data and prior normative samples. 
Furthermore, we aimed to recruit a representative study sample according to age, sex, education, 
and region. However, the study sample was not entirely representative for combinations of these 
variables (e.g., age interlocked with sex). Thus, it is uncertain if our study sample is 
representative of the general population and if the results are generalizable. Moreover, the online 
survey was based entirely on self-rated questionnaires. Although valid and widely used, people 
are often biased when they report on their own experiences, and screening questionnaires can 
overestimate prevalence of mental disorders relative to structured diagnostic interviews. Higher 
values in levels of neuroticism or other background variables associated with negative affect 










could have an impact on our results and we did not have data to adjust for these variables. 
Although we employed a representative sample according to region, the sample size limitations 
did not permit more fine-grained statistical investigations across different regions of the UK. We 
also cannot rule out that more seriously affected older adults were less likely to participate. 
 
This study examined a broad range of mental health and well-being indicators during the 
acute phase of the COVID-19 pandemic four-weeks after lockdown. According to this evidence, 
the pandemic and associated lockdown restrictions had a major impact on mental health in the 
UK. In conclusion, self-reported mental health problems are higher and psychological well-being 
and quality of life is lower compared to pre-epidemiological data in the general population. It 
remains, however, unclear how similar these previous samples are in comparison to the sample 
of the current study. 
 
Although the long-term effects of the pandemic cannot be estimated at this time, the 
short-term effect of the COVID-19 pandemic and the lockdown is likely to place a considerable 
burden on the mental health of many people. The lockdown is a major burden especially for 
younger adults, where almost two-thirds suffer from depressive or anxiety symptoms. 
Furthermore, younger people, women, the unemployed and those with low income appear to be 
more severely burdened. Access to psychological support, especially for the most burdened 
groups should be widely accessible to counteract this development. 
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Figure 1: Variability in depression severity during the COVID-19 pandemic across UK regions 


























Table 1: Study sample characteristics (N=1006). 
 
n: frequencies; %: percent 
  
Variable n % 
Sex    
Women 544 54.1 
Men 462 45.9 
Age    
18-24 98 9.7 
25-34 203 20.2 
35-44 190 18.9 
45-54 194 19.3 
55-64 173 17.2 
65+ 148 14.7 
Region   
North East  43 4.3 
North West 115 11.4 
Yorkshire & Humber  84 8.3 
East Midlands 76 7.6 
West Midlands  















Education   
Below High school   
·         No school  16 1.6 
·         Elementary school  35 3.5 
·         Trade/technical/vocational training  143 14.2 
High school  405 40.3 
Above High school   
·         College  129 12.8 
·         Bachelor's degree  163 16.2 
·         Master's degree  90 8.9 
·         Doctoral degree  13 1.3 
·         Professional degree (MD, JD, etc.)  12 1.2 










Table 2: Number of participants exceeding the cut-off score for clinically relevant 
depression/anxiety/insomnia, measures of psychological health, well-being and stress by sex. 
    Sex     
Male Female Total Statistic 
PHQ-9 10   160 (34.6) 254 (46.7) 414 (41.2) χ2(1)=15.00; p<.001 
n (%)     
GAD-7 10 
n (%) 
 144 (31.2) 248 (45.6) 392 (39.0) χ2(1)=21.84; p<.001 
    
ISI 15 
n (%) 
 116 (25.1) 167 (30.7) 283 (28.1) χ2(5)=3.86; p=.049 
    
CMD  
n (%) 
 199 (43.1) 328 (60.3) 527 (52.4) χ2(5)=29.70; p<.001 
   
PHQ-9 
M (SD)   
7.60 (7.52) 10.09 (7.65) 8.95 (7.69) 
t(1004)=-5.19; p<.001; g=.33 
    
GAD-7 
M (SD)  
6.56 (6.32) 9.28 (6.42) 8.03 (6.52) t(1004)=-6.74; p<.001; g=.43 
    
ISI  
M (SD)  
9.66 (7.09) 11.08 (6.95) 10.43 (7.04) t(1004)= -3.21; p=.001; g=.20 





62.67 (21.34) 55.16 (20.83) 58.61 (21.39) 
t(1004)=5.63; p<.001; g=.36 
    
WHO-5 
M (SD)  
14.03 (6.22) 12.05 (5.62) 12.96 (5.98) t(1004)=5.29; p<.001; g=.33 
    
PSS-10 
M (SD)  
15.66 (8.11) 19.45 (7.37) 17.71 (7.94) t(1004)=-7.77; p<.001; g=.49 
        
 
p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia 
Severity Index, GAD-7 (Generalized Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-
10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World Health Organization (WHO); WHO-
QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental 
disorder: Yes if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8.  










Table 3: Number of participants exceeding the cut-off score for clinically relevant depression/anxiety/insomnia, measures of psychological health, 
well-being and stress by age. 
  Age Total Statistic 
18-24 25-34 35-44 45-54 55-64 65+ 
PHQ-9 10  62 (63.3) 107 (52.7) 99 (52.1) 77 (39.7) 52 (30.1) 17 (11.5) 414 (41.2) χ2(5)=103.14; p<.001 
n  (%)         
GAD-7 10  58 (59.2) 99 (48.8) 93 (48.9) 72 (37.1) 52 (30.1) 18 (12.2) 392 (39.0) χ2(5)=83.77; p<.001 
n (%)         
ISI 15  34 (34.7) 61 (30.0) 61 (32.1) 64 (33.0) 44 (25.4) 19 (12.8) 283 (28.1) χ2(5)=23.95; p<.001 
n (%)         
CMD n (%)  73 (74.5) 127 (62.6) 126 (66.3) 96 (49.5) 74 (42.8) 31 (20.9) 527 (52.4) χ2(5)=108.12; p<.001 
n (%)        
PHQ-9  
M (SD)  
13.72 (7.61) 10.99 (7.66) 10.54 (7.56) 8.38 (7.26) 7.21 (7.21) 3.72 (5.07) 8.95 (7.69) F(5,1005)=32.04; p<.001; η²=.138 
       
GAD-7 
M (SD)  
10.94 (6.02) 9.52 (6.42) 9.87 (6.50) 7.60 (6.47) 6.66 (6.19) 3.86 (4.77) 8.03 (6.52) F(5,1005)=25.61; p<.001; η²=.114 
       
ISI 
M (SD)   
12.40 (6.56) 11.23 (6.82) 11.38 (6.86) 10.71 (7.55) 10.02 (7.02) 6.91 (6.07) 10.43 (7.04) F(5,1005)=10.80; p<.001; η²=.051 





46.94 (22.12) 56.73 (20.47) 53.86 (20.99) 58.91 (20.39 61.34 (21.4171.42 (16.79) 58.61 (21.39) 
F(5,1005)=21.15; p<.001; η²=.096 
       
WHO-5 
M (SD)  
11.39 (4.98) 12.80 (5.77) 12.19 (6.06) 12.71 (6.08) 13.16 (6.15 15.30 (5.84) 12.96 (5.98) F(5,1005)=6.83; p<.001; η²=.033 
       
PSS-10 
M (SD)  
21.64 (6.25) 19.34 (6.89) 19.89 (7.41) 17.61 (7.80) 16.19 (8.26 11.97 (7.36) 17.71 (7.94) 
F(5,1005)=29.87; p<.001; η²=.130 
           
 
p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia Severity Index, GAD-7 (Generalized 
Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World 
Health Organization (WHO); WHO-QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental disorder: Yes 
if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8.  










Table 4: Number of participants exceeding the cut-off score for clinically relevant depression/anxiety/insomnia, measures of psychological health, 
well-being and stress by work. 













Yes, as before 
at my 
workplace (not 
in my Home 
Office) 
Yes, but I've 






PHQ-9 10  124 (51.0) 110 (46.8) 68 (38.6) 59 (44.4) 34 (43.6) 19 (13.5) 414 (41.2) χ2(5)=58.71; p<.001 
n  (%)         
GAD-7 10  113 (46.5) 108 (46.0) 65 (36.9) 54 (40.6) 29 (37.2) 23 (16.3) 392 (39.0) χ2(5)=41.62; p<.001 
n  (%)         
ISI 15  85 (35.0) 71 (30.2) 40 (22.7) 40 (30.1) 27 (34.6) 20 (14.2) 283 (28.1) χ2(5)=24.12; p<.001 
n  (%)         
CMD   152 (62.6) 140 (59.6) 83 (47.2) 78 (58.6) 41 (52.6) 33 (23.4) 527 (52.4) χ2(5)=66.44; p<.001 
n  (%)        
PHQ-9  
M (SD)  
10.73 (8.12) 9.72 (7.20) 8.82 (7.89) 9.47 (7.52) 9.06 (7.49) 4.18 (5.62) 8.95 (7.69) 
F(5,1005)=15.033; p<.001; 
η²=.070 
        
GAD-7 
M (SD)  
9.21 (6.70) 9.05 (6.41) 7.64 (6.32) 8.42 (6.48) 8.08 (6.43) 4.38 (5.33) 8.03 (6.52) 
F(5,1005)=12.52; p<.001; 
η²=.059 
        
ISI 
M (SD)   
11.47 (7.26) 11.16 (6.68) 9.65 (6.94) 11.08 (6.93) 10.85 (7.28) 7.55 (6.60) 10.43 (7.04) 
F(5,1005)=7.20; p<.001; 
η²=.035 






52.93 (23.30) 54.86 (20.64) 61.17 (19.83) 58.27 (20.43) 61.43 (20.34) 70.21 (17.12) 58.61 (21.39) 
F(5,1008)=14.92; p<.001; 
η²=.069 
        
WHO-5 
M (SD)  
11.31 (6.29) 12.19 (5.57) 13.99 (5.71) 13.15 (5.93) 14.18 (5.81) 14.95 (5.64) 12.96 (5.98) 
F(5,1005)=9.73; p<.001; 
η²=.046 
        
PSS-10 19.09 (8.24 18.93 (7.34) 17.30 (7.65) 18.43 (7.72) 18.46 (6.97) 12.72 (7.59) 17.71 (7.94) F(5,1005)=15.12; p<.001; 










M (SD) η²=.059 
            
 
p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia Severity Index, GAD-7 (Generalized 
Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World 
Health Organization (WHO); WHO-QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental disorder: Yes 
if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8. 
  









Table 5: Number of participants exceeding the cut-off score for clinically relevant depression/anxiety/insomnia, measures of psychological health, 




< GBP 900,- 








> GBP 3,600,- 
PHQ-9 10   65 (47.1) 137 (39.9) 114 (44.5) 56 (38.1) 42 (34.4) 414 8 (41.2) χ2(4)=6.28; p=.179 
n (%)        
GAD-7 10   64 (46.4) 129 (37.6) 107 (41.8) 49 (33.3) 43 (35.2) 392 (39.0) χ2(4)=6.99; p=.137 
n (%)        
ISI 15   43 (31.2) 99 (28.9) 85 (33.2) 27 (18.4) 29 (23.8) 283 (28.1) χ2(4)=12.05; p=.017 
n (%)        
CMD n (%)  80 (58.0) 184 (53.6) 141 (55.1) 68 (46.3) 54 (44.3) 527 (52.4) χ2(4)=8.13; p=.087 
n (%)       
PHQ-9  
M (SD)  
9.95 (8.01) 9.03 (7.61) 9.50 (7.72) 7.77 (7.37) 7.85 (7.65) 8.95 (7.69) F(4,1005)=2.42; p=.047; η²=.010 
       
GAD-7 
M (SD)  
9.01 (6.91) 8.08 (6.48) 8.46 (6.41) 6.86 (6.29) 7.28 (6.47) 8.03 (6.52) F(4,1005)=2.68; p=.031; η²=.011 
       
ISI  
M (SD)  
10.95 (7.42) 10.76 (7.07) 11.29 (7.07) 8.89 (6.08) 8.93 (7.15) 10.43 (7.04) F(4,1005)=4.53; p=.001; η²=.018 





52.17 (23.03) 57.99 (21.58) 58.19 (20.92) 62.39 (19.66) 63.97 (19.99) 58.61 (21.39) 
F(4,1005)=6.42; p<.001; η²=.025 
       
WHO-5 
M (SD)  
11.75 (6.26) 12.31 (6.03) 12.88 (5.90) 14.19 (5.45) 14.84 (5.67) 12.96 (5.98) F(4,1005)=7.19; p<.001; η²=.028 
       
PSS-10 
M (SD)  
19.46 (8.61) 17.71 (8.17) 18.44 (7.42) 15.92 (7.51) 16.34 (7.56) 17.71 (7.94) F(4,1005)=5.06; p<.001; η²=.020 
           










p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia Severity Index, GAD-7 (Generalized 
Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World 
Health Organization (WHO); WHO-QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental disorder: Yes 
if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8. 
  










Table 6: Number of participants exceeding the cut-off score for clinically relevant depression/anxiety/insomnia, measures of psychological health, 
well-being and stress by physical activity. 
 
  
Days of physical activity in the last 7 days 
Total Statistic 
0 1 2 3 4 or more 
PHQ-9 10   98 (41.7) 50 (47.6) 84 (52.2) 62 (42.2) 120 (33.5) 414 (41.2) χ2(4)=18.59; p<.001 
n (%)        
GAD-7 10   87 (37.0) 45 (42.9) 79 (49.1) 59 (40.1) 122 (34.1) 392 (39.0) χ2(4)=11.63; p=.020 
n (%)        
ISI 15   69 (29.4) 37 (35.2) 54 (33.5) 47 (32.0) 76 (21.2) 283 (28.1) χ2(4)=14.64; p=.006 
n (%)        
CMD   120 (51.1) 56 (53.3) 104 (64.6) 81 (55.1) 166 (46.4) 527 (52.4) χ2(4)=15.46; p=.004 
n (%)       
PHQ-9  
M (SD)  
9.29 (7.50) 10.09 (8.30) 10.52 (7.77) 9.33 (7.71) 7.52 (7.37) 8.95 (7.69) 
F(4,1005)=5.64; p<.001; 
η²=.022 
       
GAD-7 
M (SD)  
7.71 (6.55) 8.54 (6.90) 9.16 (6.52) 8.37 (6.28) 7.44 (6.43) 8.03 (6.52) 
F(4,1005)=2.36; p=.052; 
η²=.009 
       
ISI  
M (SD)  
10.43 (6.84) 11.80 (6.91) 11.40 (6.99) 11.17 (7.54) 9.28 (6.89) 10.43 (7.04) 
F(4,1005)=4.61; p=.001; 
η²=.018 






54.54 (22.20) 55.24 (21.23) 57.09 (19.71) 59.67 (19.63) 62.52 (21.69) 58.61 (21.39) 
F(4,1005)=6.19; p<.001; 
η²=.024 
       
WHO-5 
M (SD)  
11.54 (6.03) 12.10 (5.66) 12.54 (5.79) 13.29 (5.57) 14.20 (6.04) 12.96 (5.98) 
F(4,1005)=8.22; p<.001; 
η²=.032 
       
PSS-10 
M (SD)  
17.96 (8.27) 17.55 (7.94) 18.65 (7.53) 18.25 (7.20) 16.94 (8.16) 17.71 (7.94) 
F(4,1005)=1.64; p=.162; 
η²=.007 
           
 










p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia Severity Index, GAD-7 (Generalized 
Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World 
Health Organization (WHO); WHO-QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental disorder: Yes 
if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8. 
  










Table 7. Number of participants exceeding the cut-off score for clinically relevant depression/anxiety/insomnia, measures of psychological health, 
well-being and stress by relationship status. 
  
Relationship status 
Total Statistic Not married / not 
living as married 
Married / living as 
married 
PHQ-9 10  197 (47.7) 217 (36.6) 414 (41.2) χ2(1)=12.40; p<.001 
n (%)     
GAD-7 10  181 (43.8) 211 (35.6) 392 (39.0) χ2(1)=6.96; p=.008 
n (%)     
ISI 15  129 (31.2) 154 (26.0) 283 (28.1) χ2(1)=3.34; p=.068 
n (%)     
CMD n (%)  240 (58.1) 287 (48.4) 527 (52.4) χ2(1)=9.21; p=.002 
n (%)    
PHQ-9  M (SD) 10.07 (8.04) 8.16 (7.33) 8.95 (7.69) t(1004)=3.91; p<.001; g=.25 
    
GAD-7 M (SD) 8.73 (6.65) 7.54 (6.38) 8.03 (6.52) t(1004)=2.86; p=.004; g=.18 
    
ISI  M (SD) 10.79 (7.13) 10.18 (6.98) 10.43 (7.04) t(1004)=1.35; p=.177; g=.09 
    
WHOQOL BREF 
psychological domain 
M (SD) 53.39 (22.75) 62.25 (19.60) 58.61 (21.39) 
t(1004)=-6.60; p<.001; g=.41 
    
WHO-5 M (SD) 12.08 (6.19) 13.58 (5.75) 12.96 (5.98) t(1004)=-3.94; p<.001; g=.25 
    
PSS-10 M (SD) 18.76 (8.02) 16.98 (7.81) 17.71 (7.94) t(1004)=3.52; p<.001; g=.23 
        
 
p: p-values (2-tailed); n: frequencies; M: mean score; SD: standard deviation, χ2: Chi-square; F: F-test; ISI: Insomnia Severity Index, GAD-7 (Generalized 
Anxiety Disorder 7 scale); PHQ-9: Patient Health Questionnaire 9 scale; PSS-10: Perceived Stress Scale 10; WHO-5: Well-being questionnaire of the World 
Health Organization (WHO); WHO-QOL BREF: Quality of Life questionnaire of the World Health Organization (WHO); CMD: Common mental disorder: Yes 
if PHQ-9 ≥ 10 AND/OR GAD-7 ≥ 8 vs. No if PHQ-9 < 10 AND GAD-7 < 8. The category not married / not living as married includes being single, separated, 
divorced and widowed. 
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